Peptides for cell-selective drug delivery

Trends in Pharmacological Sciences

Volumn 33, Issue 4, 2012, Pages 186-192

  Svensen, Nina ^a   Walton, Jeffrey G A ^a   Bradley, Mark ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTYLSERINE; ASPARAGINYLGLYCYLARGININE; ASPARTYLTRYPTOPHYLARGINYLVALYLISOLEUCYLISOLEUCYLPROLYLPROLYLARGINYLPROLYLSERYLALANINE; CELL PENETRATING PEPTIDE; CILENGITIDE; CYSTINYLTHREONIYLVALYLALANYLLEUCYLPROLYLGLYCYLGLYCYLTYROSYLVALYLARGINYLVALYLCYSTEINE; CYSTINYLTHREONYLPROLYLSERYLPROLYLPHENYLALANYLSERYLHISTIDYLCYSTEINE; CYSTYNYLPROLYLGLYCYLPROLYLGLUTAMINYLGLYCYLALANYLGLYCYLCYSTYSTEINE; GLUTAMINYLLEUCYL N ALKYL GLYCINE LYSINE LIKE PEPTOID N ALKYL GLYCINE LYSINE LIKE PEPTOID; GLUTAMINYLPROLYLLYSYL N ALKYL GLYCINE LYSINE LIKE PEPTOID; HISTIDYLISOLEUCYLGLUTAMINYLLEUCYLSERYLPROLYLPHENYLALANYLGLUTAMINYLSERYLTRYPTOPHYLARGININE; HOMING PEPTIDE; LEUCYLLYSYLLYSYLPROLINE; LUECYLGLYCYLALANYLSERYLTRYPTOPHYLHISTIDYLARGINYLPROLYLASPARTYLLYSINE; LUECYLGLYCYLALANYLSERYLTRYPTOPHYLHISTIDYLARGINYLPROLYLASPARTYLLYSYLCYSTYNYLCYSTYNYLLEUCYLGLYCYLTYROSYLGLUTAMINYLLYSYLARGINYLPROLYLLEUCYLPROLINE; MICROSOMAL AMINOPEPTIDASE; NANOPARTICLE; PEPTIDE; PHENYLALANYLCYSTYNYLASPARTYLGLYCYLPHENYLALANYLTYROSYLALANYLCYSTYNYLTYROSYLLYSYLASPARTYLVALINE; PROLYLPHENYLALANYLSERYLSERYLTHREONYLLYSYLTHREONINE; PROLYLTYROSYLGLUTAMINYLGLUTAMIC ACID; SERYLPHENYLALANYLHISTIDYLGLUTAMINYLPHENYLALANYLALANYLARGINYLTHREONYLLEUCYLALANYLSERINE; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANTIGEN BINDING; APOPTOSIS; CELL HOMING; CELL PROLIFERATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SCREENING; HUMAN; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; TUMOR VASCULARIZATION;

ANIMALS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; OLIGOPEPTIDES;

EID: 84859439673     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.02.002     Document Type: Review

References (70)

1. B. Wang Drug Delivery: Principles and Applications 2005 Wiley
2. G. Manish Targeted drug delivery system: a review Res. J. Chem. Sci. 1 2011 135 138
3. W.C. Aird Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms Circ. Res. 100 2007 158 173
4. W.C. Aird Phenotypic heterogeneity of the endothelium: II. Representative vascular beds Circ. Res. 100 2007 174 190
5. W. Arap Targeting the prostate for destruction through a vascular address Proc. Natl. Acad. Sci. U.S.A. 99 2002 1527 1531
6. P. Laakkonen, and K. Vuorinena Homing peptides as targeted delivery vehicles Integr. Biol. 2 2010 326 337
7. K.N. Sugahara Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328 2010 1031 1035
8. G.P. Smith Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface Science 228 1985 1315 1317
9. D. Rajotte Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display J. Clin. Invest. 102 1998 430 437
10. D. Rajotte, and E. Ruoslahti Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display J. Biol. Chem. 274 1999 11593 11598
11. L. Zhang Molecular profiling of heart endothelial cells Circulation 112 2005 1601 1611
12. v integrins as receptors for tumor targeting by circulating ligands Nat. Biotechnol. 15 1997 542 546
13. W. Arap Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 279 1998 377 380
14. M.A. Burg NG2 proteoglycan-binding peptides target tumor neovasculature Cancer Res. 59 1999 2869 2874
15. K. Porkka A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo Proc. Natl. Acad. Sci. U.S.A. 99 2002 7444 7449
16. P. Laakkonen A tumor-homing peptide with a targeting specificity related to lymphatic vessels Nat. Med. 8 2002 751 755
17. J.A. Hoffman In vivo and ex vivo selections using phage-displayed libraries T. Clackson, H.B. Lowman, Phage Display: A Practical Approach 2004 Oxford University Press 171 192
18. L. Zhang Lymphatic zip codes in premalignant lesions and tumors Cancer Res. 66 2006 5696 5706
19. N. Svensen Screening of a combinatorial homing peptide library for selective cellular delivery Angew. Chem. Int. Ed. 50 2011 6133 6136
20. V.V. Demidov Stability of peptide nucleic acids in human serum and cellular extracts Biochem. Pharmacol. 48 1994 1310 1313
21. N. Svensen Decoding a PNA encoded peptide library by PCR: the discovery of new cell surface receptor ligands Chem. Biol. 18 2011 1284 1289
22. B.W. Park Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo Nat. Biotechnol. 18 2000 194 198
23. P. Krogsgaard-Larsen Textbook of Drug Design and Discovery 2002 Taylor & Francis Chapter 4
24. H. Jhoti, and A. Leach Structure-Based Drug Discovery 2007 Springer
25. P. Jarver, and U. Langel The use of cell-penetrating peptides as a tool for gene regulation Drug Discov. Today 9 2004 395 402
26. S.W. Jones Characterisation of cell-penetrating peptide-mediated peptide delivery Br. J. Pharmacol. 145 2005 1093 1102
27. T. Endoh Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape Adv. Drug Deliv. Rev. 61 2009 704 709
28. F. Said Hassane Cell penetrating peptides: overview and applications to the delivery of oligonucleotides Cell. Mol. Life Sci. 67 2010 715 726
29. S. Trabulo Cell-penetrating peptides - mechanisms of cellular uptake and generation of delivery systems Pharmaceuticals 3 2010 961 993
30. I. Martin Building cell selectivity into CPP-mediated strategies Pharmaceuticals 3 2010 1456 1490
31. A. Elmquist VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions Exp. Cell Res. 269 2001 237 244
32. M. Green, and P.M. Loewenstein Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein Cell 55 1988 1179 1188
33. A.D. Frankel, and C.O. Pabo Cellular uptake of the tat protein from human immunodeficiency virus Cell 55 1988 1189 1193
34. E. Vives A truncated HIV-1 tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus J. Biol. Chem. 272 1997 16010 16017
35. M. Tan Selective inhibition of ErbB2-uverexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide Cancer Res. 66 2006 3764 3772
36. N. Zhou Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines J. Biol. Chem. 277 2002 17476 17485
37. E.L. Snyder Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides Cancer Res. 65 2005 10646 10650
38. E.L. Snyder Ecology drives the global distribution of human diseases PLoS Biol. 2 2004 e186
39. Y.N.P. Chen Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proc. Natl. Acad. Sci. U.S.A. 96 1999 4325 4329
40. M. Essler, and E. Ruoslahti Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature Proc. Natl. Acad. Sci. U.S.A. 99 2002 2252 2257
41. H. Myrberg Design of a tumor-homing cell-penetrating peptide Bioconjug. Chem. 19 2008 70 75
42. D. Simberg Biomimetic amplification of nanoparticle homing to tumors Proc. Natl. Acad. Sci. U.S.A. 104 2007 932 936
43. M. Mae Design of a tumor homing cell-penetrating peptide for drug delivery Int. J. Pept. Res. Ther. 15 2009 11 15
44. D. Derossi The third helix of the Antennapedia homeodomain translocates through biological membranes J. Biol. Chem. 269 1994 10444 10450
45. Cho, C.H. and Li, Z. The Chinese University of Hong Kong. Homing peptide for tumor vasculature. WO/2011/011976
46. Z. Mi Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium Mol. Ther. 8 2003 295 305
47. N. Manolios T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease Nat. Med. 3 1997 84 88
48. 99mTc-technetium labeling of antiarthritic peptides to evaluate homing and biodistribution at inflamed joints Nucl. Med. Biol. 38 2011 751 756
49. W. Mier Peptide-PNA conjugates: targeted transport of antisense therapeutics into tumors Angew. Chem. Int. Ed. 42 2003 1968 1971
50. S. Christian Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels J. Cell Biol. 163 2003 871 878
51. F. Gelain BMHP1-derived self-assembling peptides: hierarchically assembled structures with self-healing propensity and potential for tissue engineering applications ACS Nano 5 2011 1845 1859
52. Y. Kim Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand Biochemistry 45 2006 9434 9444
53. Y. Yoneda A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy Bioorg. Med. Chem. Lett. 2008 1632 1636
54. Y. Liu Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery Mol. Pharmacol. 4 2007 435 447
55. Y. Pi Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display Biomaterials 32 2011 6324 6332
56. D.M. Gerlag Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature Arthritis Res. 3 2001 357 361
57. 3 integrin for a new cancer therapy Angew. Chem. Int. Ed. 36 1997 1374 1389
58. 6 as a prognostic biomarker for non-small cell lung cancer Cancer Res. 67 2007 5889 5895
59. 5 in patients with advanced solid tumours Eur. J. Cancer 39 2003 917 926
60. W.K. Yung A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br. J. Cancer 83 2000 588 593
61. T.J. MacDonald Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium study PBTC-012 J. Clin. Oncol. 26 2008 919 924
62. K. Fink Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastome: a randomized Phase IIa study ASCO Annual Meeting 2010 Abrstract No. 2010
63. D.A. Reardon Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J. Clin. Oncol. 26 2008 5610 5617
64. M.R. Gilbert Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a Phase II trial with measures of treatment delivery J. Neurooncol. 106 2012 147 153
65. E.T. Wong Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials J. Clin. Oncol. 17 1999 2572 2578
66. R. Stupp, and M.E. Hegi Methylguanine methyltransferase testing in glioblastoma: when and how? J. Clin. Oncol. 25 2007 1459 1460
67. R. Pasqualini Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis Cancer Res. 60 2000 722 727
68. V. Gregorc Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours Br. J. Cancer 101 2009 219 224
69. V. Gregorc Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours Eur. J. Cancer 46 2010 198 206
70. V. Gregorc Phase II study of asparagine-glycine-arginine-human tumor necrosis factor α, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma J. Clin. Oncol. 28 2010 2604 2611